The Alopecia Areata Patient Journey - Episode 11
Monitoring and Setting Treatment Expectations With JAK Inhibitors in Alopecia Areata
Published on:
A panelist discusses how they determine the appropriateness of a Janus kinase (JAK) inhibitor for patients by evaluating disease severity, duration, prior treatment failures, patient comorbidities, risk factors, and laboratory results and engaging in detailed benefit-risk discussions while setting realistic expectations about treatment outcomes and potential adverse effects.
How do you decide whether a JAK inhibitor is an appropriate treatment option for a patient?
